ResMed CPO Justin Leong Receives 6,461 RSU Award

What Happened

• Justin Leong, Chief Product Officer of ResMed Inc. (RMD), was reported to have acquired 6,461 shares via a grant/award (transaction code A) on August 14, 2026. The reported acquisition price was $0.00, so the immediate cash value reported is $0. These shares are performance-based restricted stock units (RSUs) that were earned when the company certified applicable performance metrics.

Key Details

• Transaction date and price: August 14, 2026 — 6,461 RSUs acquired at $0.00 (award).
• Report filed: October 1, 2026 (the Form 4 was filed 48 days after the transaction; this is later than the usual two-business-day filing requirement).
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: The RSUs were originally granted Nov 20, 2025 as performance-based RSUs and were earned Aug 14, 2026 upon committee certification. They vest 1/3 each year on the anniversary of the grant. (See filing footnote F1.)

Context

• These were compensation RSUs that became earned based on performance certification, not an open-market purchase. Receiving an award is part of executive compensation and does not necessarily indicate a personal cash investment decision. The late filing reduces the timeliness of the disclosure for investors.